Your browser doesn't support javascript.
loading
PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs.
Kim, Eun Hye; Lee, Jongwon; Kwak, Gijung; Jang, Hochung; Kim, Hyosuk; Cho, Haeun; Jang, Yeongji; Choi, Jiwoong; Chi, Sung-Gil; Kim, Kwangmeyung; Kwon, Ick Chan; Yang, Yoosoo; Kim, Sun Hwa.
Afiliação
  • Kim EH; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
  • Lee J; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • Kwak G; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
  • Jang H; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Tech-nology, Seoul 02792, Republic of Korea.
  • Kim H; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • Cho H; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Department of Biotechnology, Korea University, Seoul 02841, Republic of Korea.
  • Jang Y; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
  • Choi J; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • Chi SG; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
  • Kim K; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • Kwon IC; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; KIST-DFCI On-Site-Lab, Department of Cancer Biology
  • Yang Y; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Tech-nology, Seoul 02792, Republic of Korea. Electronic address: ysyan
  • Kim SH; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Electronic address: sunkim@kist.re.kr.
J Control Release ; 345: 62-74, 2022 05.
Article em En | MEDLINE | ID: mdl-35263615
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article